arrow
D

Dworzak, Michael

motol university hospital
H指数:0
被引数:56

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Incidence and Risk Factors of Symptomatic Osteonecrosis in Children With Acute Lymphoblastic Leukemia-A Population-Based Analysis of the Austrian ALL-BFM Study Group

儿童急性淋巴细胞白血病患者症状性骨坏死的发病率和危险因素——奥地利ALL-BFM研究组的基于人群的分析

2026-04-010
PRE
Children with chronic-phase chronic myeloid leukemia: characteristics and outcomes from the International Registry of Childhood CML

慢性期慢性髓性白血病患儿:来自国际儿童CML登记研究的特征和结局

2026-04-011
PRE
ADVANCED DRUG RESPONSE PROFILING AND IMMUNOPHENOTYPING TO PRIORITIZE TREATMENT OPTIONS FOR PEDIATRIC MDS WITH EXCESS BLASTS
2025-11-010
OAAI
GENETIC LANDSCAPE AND OUTCOMES AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION IN CHILDREN AND ADOLESCENTS WITH THERAPY-RELATED MYELOID NEOPLASMS

治疗相关性髓系肿瘤儿童和青少年造血干细胞移植后的遗传景观和结局

2025-11-010
OA
IMPROVED ENGRAFTMENT FOLLOWING A TREOSULFAN-FLUDARABINE CONDITIONING REGIMEN COMPARED TO THIOTEPA-FLUDARABINE IN PATIENTS WITH REFRACTORY CYTOPENIA OF CHILDHOOD

与噻替帕-氟达拉滨相比,TREOSULFAN-氟达拉滨预处理方案改善了儿童难治性血细胞减少症患者的植入

2025-11-010
OAAI
OUTCOMES OF RABBIT VS. HORSE ANTI-THYMOCYTE GLOBULIN IN IMMUNOSUPPRESSIVE THERAPY FOR REFRACTORY CYTOPENIA OF CHILDHOOD
2025-11-010
OAAI
LONG-TERM OUTCOME OF AN OBSERVATIONAL APPROACH IN PATIENTS WITH NRAS-MUTATED JUVENILE MYELOMONOCYTIC LEUKEMIA AND ABSENCE OF HIGH RISK FEATURES
2025-11-010
OA
INTEGRATED IMMUNOPHENOTYPING AND DRUG RESPONSE PROFILING REVEALS SUBTYPE-SPECIFIC SUSCEPTIBILITIES IN PEDIATRIC MDS WITH EXCESS BLASTS
2025-11-010
OA
Diagnosis and Management of AML in Pediatric Patients: Consensus Recommendations from an International Expert Panel

儿童急性髓系白血病(AML)的诊断与管理:国际专家小组的共识建议

Blood
IF23.1
2025-10-220
PRE
Results in pediatric T-ALL patients treated in trial AIEOP-BFM ALL 2009: Prognostic factors in the context of modern risk-adapted therapy

AIEOP-BFM ALL 2009试验中接受治疗的儿童T-ALL患者的结果:现代风险适应疗法背景下的预后因素

2025-09-020
OAAI
Image-based drug screening combined with molecular profiling identifies signatures and drivers of therapy resistance in pediatric AML

基于图像的药物筛选与分子谱分析相结合,可识别儿童急性髓系白血病(AML)中治疗耐药性的特征和驱动因素。

2025-08-200
OAAI
Age-dependent phenotypic and molecular evolution of pediatric MDS arising from GATA2 deficiency

年龄依赖性的表型和分子进化:源于GATA2缺乏的儿科MDS

2025-07-150
OAAI
No evidence of leukaemia (NEL) as a response criteria in paediatric AML: a multicentre analysis

无证据显示白血病(NEL)作为儿童急性髓系白血病(AML)的治疗反应标准:一项多中心分析

2025-06-010
OA
Flow-cytometric MRD detection in pediatric T-ALL: a multicenter AIEOP-BFM consensus-based guided standardized approach
2025-03-010
PRE
Results in Pediatric T-ALL Patients Treated in Trial AIEOP-BFM ALL 2009: Exploring Prognostic Factors in the Context of Modern Risk Adapted Therapy

儿童T-ALL患者在接受AIEOP-BFM ALL 2009试验治疗后的结果:在现代化风险适应治疗背景下探索预后因素

BLOOD
IF23.1
2024-11-050
PRE